Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
PhenoMiner Database Result        View data table  |  Download data table  |  View compact data table        


Generate Chart For    
    (Chart displayed below)
Rat Strains

{{sample.term}}
Measurement Methods

{{method.term}}
Age

{{ageRange}}
Experimental Conditions

     {{ cond }}

Minimum Value:    Maximum Value:    Sex:


 
Options:  View chart  |  Download data table  |  View compact data table
Study IDStudyExperiment NameExperiment NotesStrain Ont IDStrainSexAge# of AnimalsSample NotesClinical Measurement Ont IDPhenotypeFormulaClinical Measurement NotesAverage TypeValueUnitsSEMSDMethod Ont IDMethodMethod SiteMethod DurationMethod NotesPost Insult TypePost Insult Time ValuePost Insult Time UnitConditionsRecord IDCondition 1aCondition 1b
1162Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.body massRS:0000229DA.PVG.1AV1-(D4Rat63-D4Rat203)both200 days to 120 days10CMO:0001400maximum body weight loss to initial body weight ratio6.6%2.57.9057MMO:0000016body weighing method0.0squalene (200 ul) 69808squalene (200 ul)
1162Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.body massRS:0000229DA.PVG.1AV1-(D4Rat63-D4Rat203)both200 days to 120 days10CMO:0001400maximum body weight loss to initial body weight ratio14.6%1.85.6921MMO:0000016body weighing method0.0type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) 69810type II collagen (500 ug) Freund's incomplete adjuvant (100 ul)
1162Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.body massRS:0000229DA.PVG.1AV1-(D4Rat63-D4Rat203)both200 days to 120 days10CMO:0001400maximum body weight loss to initial body weight ratio12.6%2.78.5381MMO:0000016body weighing method0.0pristane (150 ul) 69812pristane (150 ul)
1301Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.joint integrity traitRS:0000229DA.PVG.1AV1-(D4Rat63-D4Rat203)both0 days37CMO:0001453percentage of study population developing experimental arthritis during a period of time5%MMO:0000163in vivo visual assessment0.0Freund's incomplete adjuvant (200 ul) 70201Freund's incomplete adjuvant (200 ul)
1162Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.joint integrity traitRS:0000229DA.PVG.1AV1-(D4Rat63-D4Rat203)both200 days to 120 days10CMO:0001453percentage of study population developing experimental arthritis during a period of time100%MMO:0000163in vivo visual assessment0.0squalene (200 ul) 69721squalene (200 ul)
1162Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.joint integrity traitRS:0000229DA.PVG.1AV1-(D4Rat63-D4Rat203)both200 days to 120 days10CMO:0001453percentage of study population developing experimental arthritis during a period of time100%MMO:0000163in vivo visual assessment0.0type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) 69723type II collagen (500 ug) Freund's incomplete adjuvant (100 ul)
1162Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.joint integrity traitRS:0000229DA.PVG.1AV1-(D4Rat63-D4Rat203)both200 days to 120 days10CMO:0001453percentage of study population developing experimental arthritis during a period of time90%MMO:0000163in vivo visual assessment0.0pristane (150 ul) 69725pristane (150 ul)
1301Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.joint integrity traitRS:0000229DA.PVG.1AV1-(D4Rat63-D4Rat203)both0 days37CMO:0001450post-insult time to onset of experimental arthritis14d0.00.0MMO:0000163in vivo visual assessment0.0Freund's incomplete adjuvant (200 ul) 70202Freund's incomplete adjuvant (200 ul)
1162Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.joint integrity traitRS:0000229DA.PVG.1AV1-(D4Rat63-D4Rat203)both200 days to 120 days10CMO:0001450post-insult time to onset of experimental arthritis16.9d0.61.8974MMO:0000163in vivo visual assessment0.0squalene (200 ul) 69789squalene (200 ul)
1162Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.joint integrity traitRS:0000229DA.PVG.1AV1-(D4Rat63-D4Rat203)both200 days to 120 days10CMO:0001450post-insult time to onset of experimental arthritis16.4d0.82.5298MMO:0000163in vivo visual assessment0.0type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) 69791type II collagen (500 ug) Freund's incomplete adjuvant (100 ul)
1162Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.joint integrity traitRS:0000229DA.PVG.1AV1-(D4Rat63-D4Rat203)both200 days to 120 days10CMO:0001450post-insult time to onset of experimental arthritis15.5d0.82.5298MMO:0000163in vivo visual assessment0.0pristane (150 ul) 69793pristane (150 ul)
1162Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.orosomucoid 1 amountblood alpha-1-acid glycoprotein amountRS:0000229DA.PVG.1AV1-(D4Rat63-D4Rat203)both180 days to 120 days10CMO:0001466serum orosomucoid 1 level480mg/lMMO:0000439radial immunodiffusion assay0.0radial immunodiffusion assaysqualene (200 ul) 69768squalene (200 ul)
1162Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.orosomucoid 1 amountblood alpha-1-acid glycoprotein amountRS:0000229DA.PVG.1AV1-(D4Rat63-D4Rat203)both180 days to 120 days10CMO:0001466serum orosomucoid 1 level660mg/lMMO:0000439radial immunodiffusion assay0.0radial immunodiffusion assaytype II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) 69770type II collagen (500 ug) Freund's incomplete adjuvant (100 ul)
1162Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.orosomucoid 1 amountblood alpha-1-acid glycoprotein amountRS:0000229DA.PVG.1AV1-(D4Rat63-D4Rat203)both180 days to 120 days10CMO:0001466serum orosomucoid 1 level750mg/lMMO:0000439radial immunodiffusion assay0.0radial immunodiffusion assaypristane (150 ul) 69772pristane (150 ul)